Compare · AQST vs NVO
AQST vs NVO
Side-by-side comparison of Aquestive Therapeutics Inc. (AQST) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AQST and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 431.0x AQST ($516.9M).
- Over the past year, AQST is down 2.5% and NVO is down 22.5% - AQST leads by 20.0 points.
- Both names hit the wire about 4 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 6 for AQST).
- Company
- Aquestive Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $4.13+4.56%
- $50.31-2.25%
- Market cap
- $516.9M
- $222.81B
- 1M return
- -3.40%
- +15.47%
- 1Y return
- -2.48%
- -22.53%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 4
- 4
- Recent ratings
- 6
- 25
Aquestive Therapeutics Inc.
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest AQST
- President and CEO Barber Daniel sold $100,192 worth of shares (25,000 units at $4.01), decreasing direct ownership by 4% to 610,574 units (SEC Form 4)
- SEC Form 424B3 filed by Aquestive Therapeutics Inc.
- SEC Form EFFECT filed by Aquestive Therapeutics Inc.
- Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
- SEC Form S-3 filed by Aquestive Therapeutics Inc.
- Director Krop Julie exercised 25,000 shares at a strike of $0.71 and sold $125,392 worth of shares (25,000 units at $5.02) as part of a pre-agreed trading plan (SEC Form 4)
- President and CEO Barber Daniel sold $104,010 worth of shares (25,000 units at $4.16), decreasing direct ownership by 4% to 635,574 units (SEC Form 4)
- SEC Form 4 filed by Director Morris Timothy E
- SEC Form 4 filed by Director Krop Julie
- SEC Form 4 filed by Director Jenkins Abigail L.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S